In this issue:
Use of clinical and echocardiographic evaluation to assess HF risk
Optimisation of evidence-based HF medications after acute admission
Implantable haemodynamic monitors improve survival in HFREF
Neuropeptide Y: elevated in HF and predicts outcomes
Bariatric surgery and weight-loss pharmacotherapies in HF with obesity
Prognostic value of HGI in HFREF
GFR decline after dapagliflozin in HFMREF/HFPEF
First-phase EF predicts adverse outcomes in HF
CV medication utilisation trends among US veterans with HF or CAD + diabetes
Please login below to download this issue (PDF)